Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747553 | 0.91 | ADRB3 (0.74) | ADRB3ADRB2 | |
| Hydrochloric Acid SCHEMBL11744017 | 0.90 | ADRB3 (0.72) | ADRB3ADRB2 | |
| Hydrochloric Acid SCHEMBL11669931 | 0.88 | ADRB3 (0.71) | ADRB3ADRB2 | |
| SCHEMBL7615164 | 0.84 | ADRB3 (0.69) | ADRB3ADRB2 | |
| SCHEMBL7610750 | 0.84 | ADRB3 (0.69) | ADRB3ADRB2 | |
| SCHEMBL7605269 | 0.84 | ADRB3 (0.69) | ADRB3ADRB2 | |
| Soterenol SCHEMBL119138 | 0.83 | ADRB3 (1.00) | ADRB3ADRB2 | |
| SCHEMBL7603020 | 0.82 | ADRB3 (0.80) | ADRB3ADRB2 | |
| SCHEMBL7115909 | 0.82 | ADRB3 (0.80) | ADRB3ADRB2 | |
| SCHEMBL7610796 | 0.82 | ADRB3 (0.67) | ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | disclosed |
| US-9907765-B2 | Treatment of connective tissue diseases of the skin | CIPHER PHARMACEUTICALS INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2017-06-08 | — | — | US | disclosed |
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEVELOPMENT A/S (DK) | 2013-09-12 | — | — | US | disclosed |
| US-8426475-B2 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S (DK) | 2013-04-23 | — | — | US | disclosed |
| EP-1719507-B1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719507-A1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | Astion Development A/S (DK) | 2006-11-08 | — | — | EP | disclosed |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB3 7/4885ADRB2 1/4885 |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ADRB2, ADRB1, ADRA2A | ADRB3 7/4885ADRB2 1/4885 |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB3 7/4885ADRB2 1/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB3 7/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.